18F-FAPI-04 PET/CT评估不可切除肝癌90Y-SIRT后病灶活性与疗效的初步探索
本研究回顾性纳入31例接受90Y微球选择性内放射治疗(SIRT)的不可切除肝细胞癌(uHCC)患者,比较治疗后18F-FAPI-04 PET/CT、18F-FDG PET/CT与CECT/MRI对靶病灶及肝内病灶的检出效能,并评估疗效与预后价值。结果显示18F-FAPI-04敏感性较高但特异性有限,其PERCIST及部分摄取参数可能具有预后价值。
要点
- 18F-FAPI-04对肝内病灶敏感性高于18F-FDG,但特异性较低。
- 18F-FAPI-04 PERCIST与mRECIST一致率约73.3%–75.0%。
- 治疗后FAPI摄取容积参数及ΔSULpeak-target%可能有预后价值。
核心结论
- 在uHCC患者90Y-SIRT后,18F-FAPI-04 PET/CT检测肝内病灶敏感性高但特异性有限,其治疗后参数可能具有预后价值。
研究设计与样本
- 回顾性纳入2024年2月至2025年6月接受90Y-SIRT并随后行18F-FDG和/或18F-FAPI-04 PET/CT评估的uHCC患者,共31例(平均年龄51±11岁,范围38-75;男性28例)。
主要发现
- 18F-FAPI-04 PET/CT对靶病灶和全部肝内病灶的敏感性与CECT/MRI相当(靶病灶95.2% vs. 81.0%,全部肝内病灶80.0% vs. 88.2%,均P>0.05)。
- 18F-FAPI-04 PET/CT对靶病灶和肝内病灶的特异性低于CECT/MRI(靶病灶64.3% vs. 100.0%,P=0.063;肝内病灶40.0% vs. 100.0%,P=0.031)。
- 与18F-FDG PET/CT相比,18F-FAPI-04 PET/CT检测全部肝内病灶敏感性更高(78.9% vs. 55.3%,P=0.023)但特异性更低(43.7% vs. 100.0%,P=0.016)。
- 18F-FDG PERCIST与mRECIST在靶病灶和全身病灶的一致率分别为69.2%和71.4%;18F-FAPI-04 PERCIST与mRECIST分别为73.3%和75.0%。
- mRECIST评估结果与总生存期(OS)显著相关,18F-FAPI-04 PET/CT PERCIST提示进展患者OS更差。
关键数值与推荐
- 靶病灶敏感性:18F-FAPI-04 95.2% vs. CECT/MRI 81.0%(P>0.05)。
- 全部肝内病灶敏感性:18F-FAPI-04 80.0% vs. CECT/MRI 88.2%(P>0.05)。
- 肝内病灶特异性:18F-FAPI-04 40.0% vs. CECT/MRI 100.0%(P=0.031)。
- 全部肝内病灶:18F-FAPI-04敏感性78.9% vs. 18F-FDG 55.3%(P=0.023),特异性43.7% vs. 100.0%(P=0.016)。
临床怎么用
- 18F-FAPI-04 PET/CT可用于90Y-SIRT后肝内病灶的敏感探测,但需结合CECT/MRI等以弥补特异性不足。
- 治疗后18F-FAPI-04 PET/CT参数及PERCIST评估可辅助预后判断。
局限性
- 为初步探索性、回顾性研究,样本量31例,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to preliminarily evaluate the value of 18F-FAPI-04 PET/CT in assessing target lesions viability and treatment response in patients with unresectable hepatocellular carcinoma (uHCC) following Yttrium-90(90Y) microsphere selective internal radiation therapy (SIRT). METHODS: Patients with uHCC who underwent 90Y-SIRT and subsequently received post-SIRT 18F-FDG and/or 18F-FAPI-04 PET/CT evaluations from February 2024 to June 2025 were retrospectively included. Visual assessments of post-SIRT target lesions were performed based on CECT/MRI, 18F-FDG PET/CT, and 18F-FAPI-04 PET/CT, and lesion detection efficacy was compared among the three methods. The SUVmax, peak standardized uptake value corrected for lean body mass (SULpeak), metabolic/FAPI-avid tumor volumetric parameters of target and whole-body lesions before and after SIRT were measured, and the percentage changes (Δ%) were calculated. Post-SIRT response was assessed using mRECIST 1.1, 18F-FDG, and 18F-FAPI-04 PERCIST criteria. RESULTS: A total of 31 patients were included (mean age 51 ± 11, range: 38-75; males: 28). Post-SIRT 18F-FAPI-04 PET/CT showed comparable sensitivity to CECT/MRI for both target and all intrahepatic lesions (target lesions: 95.2% vs. 81.0%, all intrahepatic lesions: 80.0% vs. 88.2%, both P > 0.05), but lower specificity (target lesions: 64.3% vs. 100.0%, P = 0.063; intrahepatic lesions: 40.0% vs. 100.0%, P = 0.031). Compared with 18F-FDG PET/CT, 18F-FAPI-04 PET/CT had significantly higher sensitivity for detecting all intrahepatic lesions (78.9% vs. 55.3%, P = 0.023) but lower specificity (43.7% vs. 100.0%, P = 0.016). The concordance rates between 18F-FDG PERCIST and mRECIST were 69.2% and 71.4% for target and whole-body lesions, respectively; between 18F-FAPI-04 PERCIST and mRECIST, they were 73.3% and 75.0%, respectively. The mRECIST assessment results were significantly correlated with overall survival (OS), while 18F-FAPI-04 PET/CT PERCIST indicated that progressive patients had worse OS. Post-SIRT lesion uptake, FAPI-avid tumor volumetric parameters on 18F-FAPI-04 PET/CT, as well as ΔSULpeak-target%, may have prognostic value. CONCLUSION: In uHCC patients undergoing 90Y-SIRT,18F-FAPI-04 PET/CT shows high sensitivity but limited specificity for detecting post-SIRT intrahepatic lesions. Post-SIRT 18F-FAPI-04 PET/CT parameters may carry prognostic value. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2500107817), registered on 19 August 2025, retrospectively registered.
引用
- Gong H, Cheng Y, Liu Z, et al. The value of 18F-FAPI-04 PET/CT in the assessment of unresectable hepatocellular carcinoma after selective internal radiation therapy: a preliminary exploratory study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42176195. doi:10.1007/s00259-026-07919-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。